1
|
Iruzubieta P, Pellerin D, Bergareche A, Albajar I, Mondragón E, Vinagre A, Fernández-Torrón R, Moreno F, Equiza J, Campo-Caballero D, Poza JJ, Ruibal M, Formica A, Dicaire MJ, Danzi MC, Zuchner S, Croitoru I, Ruiz M, Schlüter A, Casasnovas C, Pujol A, Brais B, Houlden H, López de Munain A, Ruiz-Martínez J. Frequency and phenotypic spectrum of spinocerebellar ataxia 27B and other genetic ataxias in a Spanish cohort of late-onset cerebellar ataxia. Eur J Neurol 2023; 30:3828-3833. [PMID: 37578187 DOI: 10.1111/ene.16039] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Revised: 07/30/2023] [Accepted: 08/10/2023] [Indexed: 08/15/2023]
Abstract
BACKGROUND AND PURPOSE Dominantly inherited GAA repeat expansions in the fibroblast growth factor 14 (FGF14) gene have recently been shown to cause spinocerebellar ataxia 27B (SCA27B). We aimed to study the frequency and phenotype of SCA27B in a cohort of patients with unsolved late-onset cerebellar ataxia (LOCA). We also assessed the frequency of SCA27B relative to other genetically defined LOCAs. METHODS We recruited a consecutive series of 107 patients with LOCA, of whom 64 remained genetically undiagnosed. We screened these 64 patients for the FGF14 GAA repeat expansion. We next analysed the frequency of SCA27B relative to other genetically defined forms of LOCA in the cohort of 107 patients. RESULTS Eighteen of 64 patients (28%) carried an FGF14 (GAA)≥250 expansion. The median (range) age at onset was 62.5 (39-72) years. The most common clinical features included gait ataxia (100%) and mild cerebellar dysarthria (67%). In addition, episodic symptoms and downbeat nystagmus were present in 39% (7/18) and 37% (6/16) of patients, respectively. SCA27B was the most common cause of LOCA in our cohort (17%, 18/107). Among patients with genetically defined LOCA, SCA27B was the main cause of pure ataxia, RFC1-related disease of ataxia with neuropathy, and SPG7 of ataxia with spasticity. CONCLUSION We showed that SCA27B is the most common cause of LOCA in our cohort. Our results support the use of FGF14 GAA repeat expansion screening as a first-tier genetic test in patients with LOCA.
Collapse
Affiliation(s)
- Pablo Iruzubieta
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology London and The National Hospital for Neurology and Neurosurgery, University College London, London, UK
| | - David Pellerin
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology London and The National Hospital for Neurology and Neurosurgery, University College London, London, UK
- Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
| | - Alberto Bergareche
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| | - Inés Albajar
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
| | - Elisabet Mondragón
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| | - Ana Vinagre
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| | - Roberto Fernández-Torrón
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| | - Fermín Moreno
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| | - Jon Equiza
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
| | - David Campo-Caballero
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
| | - Juan José Poza
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
| | - Marta Ruibal
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
| | - Alessandro Formica
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
| | - Marie-Josée Dicaire
- Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
| | - Matt C Danzi
- Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - Stephan Zuchner
- Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - Ioana Croitoru
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| | - Montserrat Ruiz
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Agatha Schlüter
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Carlos Casasnovas
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
- Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain
| | - Aurora Pujol
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
- Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
| | - Bernard Brais
- Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada
| | - Henry Houlden
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology London and The National Hospital for Neurology and Neurosurgery, University College London, London, UK
| | - Adolfo López de Munain
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| | - Javier Ruiz-Martínez
- Department of Neurology, Donostia University Hospital, Biodonostia Health Research Institute, Donostia-San Sebastián, Spain
- CIBERNED Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas-Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
| |
Collapse
|
2
|
Konjevod M, Sáiz J, Barbas C, Bergareche A, Ardanaz E, Huerta JM, Vinagre-Aragón A, Erro ME, Chirlaque MD, Abilleira E, Ibarluzea JM, Amiano P. A Set of Reliable Samples for the Study of Biomarkers for the Early Diagnosis of Parkinson's Disease. Front Neurol 2022; 13:844841. [PMID: 35707037 PMCID: PMC9189395 DOI: 10.3389/fneur.2022.844841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Accepted: 04/19/2022] [Indexed: 11/30/2022] Open
Abstract
Background Parkinson's disease (PD) is a progressive neurodegenerative disorder, diagnosed according to the clinical criteria that occur in already advanced stages of PD. The definition of biomarkers for the early diagnosis of PD represents a challenge that might improve treatment and avoid complications in this disease. Therefore, we propose a set of reliable samples for the identification of altered metabolites to find potential prognostic biomarkers for early PD. Methods This case–control study included plasma samples of 12 patients with PD and 21 control subjects, from the Spanish European Prospective Investigation into Cancer and Nutrition (EPIC)-Navarra cohort, part of the EPIC-Spain study. All the case samples were provided by healthy volunteers who were followed-up for 15.9 (±4.1) years and developed PD disease later on, after the sample collection. Liquid chromatography coupled to tandem mass spectrometry was used for the analysis of samples. Results Out of 40 that were selected and studied due to their involvement in established cases of PD, seven significantly different metabolites between PD cases and healthy control subjects were obtained in this study (benzoic acid, palmitic acid, oleic acid, stearic acid, myo-inositol, sorbitol, and quinolinic acid). These metabolites are related to mitochondrial dysfunction, the oxidative stress, and the mechanisms of energy production. Conclusion We propose the samples from the EPIC study as reliable and invaluable samples for the search of early biomarkers of PD. Likewise, this study might also be a starting point in the establishment of a well-founded panel of metabolites that can be used for the early detection of this disease.
Collapse
Affiliation(s)
- Marcela Konjevod
- Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia
- Facultad de Farmacia, Centro de Metabolómica y Bioanálisis, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
| | - Jorge Sáiz
- Facultad de Farmacia, Centro de Metabolómica y Bioanálisis, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
- *Correspondence: Jorge Sáiz
| | - Coral Barbas
- Facultad de Farmacia, Centro de Metabolómica y Bioanálisis, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
| | - Alberto Bergareche
- Department of Neurology, University Hospital Donostia, San Sebastián, Spain
- Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain
- Biomedical Research Networking Centre Consortium for the Area of Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
- Alberto Bergareche
| | - Eva Ardanaz
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - José Ma Huerta
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Instituto Murciano de Investigación Biosanitaria, Murcia, Spain
| | - Ana Vinagre-Aragón
- Department of Neurology, University Hospital Donostia, San Sebastián, Spain
| | - Ma Elena Erro
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
- Department of Neurology, Navarra Hospital Complex, Pamplona, Spain
| | - Ma Dolores Chirlaque
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Instituto Murciano de Investigación Biosanitaria, Murcia, Spain
| | - Eunate Abilleira
- Ministry of Health of the Basque Government, Public Health Laboratory in Gipuzkoa, San Sebastián, Spain
- Epidemiology of Chronic and Comunnicable Diseases Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Jesús Ma Ibarluzea
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain
- Environmental Epidemiology and Child Development Area, Biodonostia Health Research Institute, San Sebastián, Spain
- Faculty of Psychology, University of the Basque Country UPV/EHU, San Sebastian, Spain
| | - Pilar Amiano
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Ministry of Health of the Basque Government, Public Health Laboratory in Gipuzkoa, San Sebastián, Spain
- Epidemiology of Chronic and Comunnicable Diseases Area, Biodonostia Health Research Institute, San Sebastián, Spain
| |
Collapse
|
3
|
Dileone M, Ammann C, Catanzaro V, Pagge C, Piredda R, Monje MH, Navalpotro-Gomez I, Bergareche A, Rodríguez-Oroz MC, Vela-Desojo L, Alonso-Frech F, Catalán MJ, Molina JA, López-Ariztegu N, Oliviero A, Obeso JA, Foffani G. Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: A randomized controlled trial. Brain Stimul 2022; 15:857-860. [DOI: 10.1016/j.brs.2022.05.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 05/10/2022] [Accepted: 05/15/2022] [Indexed: 11/02/2022] Open
|
4
|
Gonzalez-Riano C, Saiz J, Barbas C, Bergareche A, Huerta JM, Ardanaz E, Konjevod M, Mondragon E, Erro ME, Chirlaque MD, Abilleira E, Goñi-Irigoyen F, Amiano P. Prognostic biomarkers of Parkinson's disease in the Spanish EPIC cohort: a multiplatform metabolomics approach. NPJ Parkinsons Dis 2021; 7:73. [PMID: 34400650 PMCID: PMC8368017 DOI: 10.1038/s41531-021-00216-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 06/22/2021] [Indexed: 02/07/2023] Open
Abstract
The lack of knowledge about the onset and progression of Parkinson's disease (PD) hampers its early diagnosis and treatment. Metabolomics might shed light on the PD imprint seeking a broader view of the biochemical remodeling induced by this disease in an early and pre-symptomatic stage and unveiling potential biomarkers. To achieve this goal, we took advantage of the great potential of the European Prospective Study on Nutrition and Cancer (EPIC) cohort to apply metabolomics searching for early diagnostic PD markers. This cohort consisted of healthy volunteers that were followed for around 15 years until June 2011 to ascertain incident PD. For this untargeted metabolomics-based study, baseline preclinical plasma samples of 39 randomly selected individuals that developed PD (Pre-PD group) and the corresponding control group were analyzed using a multiplatform approach. Data were statistically analyzed and exposed alterations in 33 metabolites levels, including significantly lower levels of free fatty acids (FFAs) in the preclinical samples from PD subjects. These results were then validated by adopting a targeted HPLC-QqQ-MS approach. After integrating all the metabolites affected, our finding revealed alterations in FFAs metabolism, mitochondrial dysfunction, oxidative stress, and gut-brain axis dysregulation long before the development of PD hallmarks. Although the biological purpose of these events is still unknown, the remodeled metabolic pathways highlighted in this work might be considered worthy prognostic biomarkers of early prodromal PD. The findings revealed by this work are of inestimable value since this is the first study conducted with samples collected many years before the disease development.
Collapse
Affiliation(s)
- Carolina Gonzalez-Riano
- grid.8461.b0000 0001 2159 0415Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, Madrid, Spain
| | - Jorge Saiz
- grid.8461.b0000 0001 2159 0415Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, Madrid, Spain
| | - Coral Barbas
- grid.8461.b0000 0001 2159 0415Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, Madrid, Spain
| | - Alberto Bergareche
- grid.432380.eNeurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain ,grid.414651.3Disorders Unit, Department of Neurology, University Hospital Donostia, San Sebastián, Spain ,grid.418264.d0000 0004 1762 4012Biomedical Research Networking Centre Consortium for the Area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - José Mª Huerta
- grid.452553.0Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain ,grid.413448.e0000 0000 9314 1427CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Eva Ardanaz
- grid.413448.e0000 0000 9314 1427CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain ,grid.419126.90000 0004 0375 9231Instituto de Salud Pública de Navarra, Pamplona, Spain
| | - Marcela Konjevod
- grid.4905.80000 0004 0635 7705Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia
| | - Elisabet Mondragon
- grid.432380.eNeurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - M. E. Erro
- grid.508840.10000 0004 7662 6114Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain
| | - M. Dolores Chirlaque
- grid.452553.0Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain ,grid.413448.e0000 0000 9314 1427CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Eunate Abilleira
- grid.432380.ePublic Health Laboratory in Gipuzkoa, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Fernando Goñi-Irigoyen
- grid.413448.e0000 0000 9314 1427CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain ,grid.432380.ePublic Health Laboratory in Gipuzkoa, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Pilar Amiano
- grid.413448.e0000 0000 9314 1427CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain ,grid.432380.ePublic Health Laboratory in Gipuzkoa, Biodonostia Health Research Institute, San Sebastián, Spain
| |
Collapse
|
5
|
Lopez-de-Ipina K, Solé-Casals J, Sánchez-Méndez JI, Romero-Garcia R, Fernandez E, Requejo C, Poologaindran A, Faúndez-Zanuy M, Martí-Massó JF, Bergareche A, Suckling J. Analysis of Fine Motor Skills in Essential Tremor: Combining Neuroimaging and Handwriting Biomarkers for Early Management. Front Hum Neurosci 2021; 15:648573. [PMID: 34168544 PMCID: PMC8219239 DOI: 10.3389/fnhum.2021.648573] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Accepted: 04/19/2021] [Indexed: 12/22/2022] Open
Abstract
Essential tremor (ET) is a highly prevalent neurological disorder characterized by action-induced tremors involving the hand, voice, head, and/or face. Importantly, hand tremor is present in nearly all forms of ET, resulting in impaired fine motor skills and diminished quality of life. To advance early diagnostic approaches for ET, automated handwriting tasks and magnetic resonance imaging (MRI) offer an opportunity to develop early essential clinical biomarkers. In this study, we present a novel approach for the early clinical diagnosis and monitoring of ET based on integrating handwriting and neuroimaging analysis. We demonstrate how the analysis of fine motor skills, as measured by an automated Archimedes' spiral task, is correlated with neuroimaging biomarkers for ET. Together, we present a novel modeling approach that can serve as a complementary and promising support tool for the clinical diagnosis of ET and a large range of tremors.
Collapse
Affiliation(s)
- Karmele Lopez-de-Ipina
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
- EleKin Research Group, Department of System Engineering and Automation, University of the Basque Country UPV/EHU, Donostia-San Sebastian, Spain
| | - Jordi Solé-Casals
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
- Data and Signal Processing Research Group, University of Vic-Central University of Catalonia, Barcelona, Spain
| | - José Ignacio Sánchez-Méndez
- EleKin Research Group, Department of System Engineering and Automation, University of the Basque Country UPV/EHU, Donostia-San Sebastian, Spain
| | | | - Elsa Fernandez
- EleKin Research Group, Department of System Engineering and Automation, University of the Basque Country UPV/EHU, Donostia-San Sebastian, Spain
| | - Catalina Requejo
- Cajal Institute, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Anujan Poologaindran
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
- The Alan Turing Institute, British Library, London, United Kingdom
| | | | - José Félix Martí-Massó
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, Donostia-San Sebastian, Spain
- Movement Disorders Unit, Department of Neurology, Donostia University Hospital, Donostia-San Sebastian, Spain
- Biomedical Research Networking Centre Consortium for the Area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Alberto Bergareche
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, Donostia-San Sebastian, Spain
- Movement Disorders Unit, Department of Neurology, Donostia University Hospital, Donostia-San Sebastian, Spain
- Biomedical Research Networking Centre Consortium for the Area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - John Suckling
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
6
|
Vinagre-Aragón A, Campo-Caballero D, Mondragón-Rezola E, Pardina-Vilella L, Hernandez Eguiazu H, Gorostidi A, Croitoru I, Bergareche A, Ruiz-Martinez J. A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene. Front Neurol 2021; 12:635396. [PMID: 33763016 PMCID: PMC7982912 DOI: 10.3389/fneur.2021.635396] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Accepted: 01/13/2021] [Indexed: 11/27/2022] Open
Abstract
Parkinson's disease (PD) is characterized by a great clinical heterogeneity. Nevertheless, the biological drivers of this heterogeneity have not been completely elucidated and are likely to be complex, arising from interactions between genetic, epigenetic, and environmental factors. Despite this heterogeneity, the clinical patterns of monogenic forms of PD have usually maintained a good clinical correlation with each mutation once a sufficient number of patients have been studied. Mutations in LRRK2 are the most commonly known genetic cause of autosomal dominant PD known to date. Furthermore, recent genome-wide association studies have revealed variations in LRRK2 as significant risk factors also for the development of sporadic PD. The LRRK2-R1441G mutation is especially frequent in the population of Basque ascent based on a possible founder effect, being responsible for almost 50% of cases of familial PD in our region, with a high penetrance. Curiously, Lewy bodies, considered the neuropathological hallmark of PD, are absent in a significant subset of LRRK2-PD cases. Indeed, these cases appear to be associated with a less aggressive primarily pure motor phenotype. The aim of our research is to examine the clinical phenotype of R1441G-PD patients, more homogeneous when we compare it with sporadic PD patients or with patients carrying other LRRK2 mutations, and reflect on the value of the observed correlation in the genetic forms of PD. The clinical heterogeneity of PD leads us to think that there may be as many different diseases as the number of people affected. Undoubtedly, genetics constitutes a relevant key player, as it may significantly influence the phenotype, with differences according to the mutation within the same gene, and not only in familial PD but also in sporadic forms. Thus, extending our knowledge regarding genetic forms of PD implies an expansion of knowledge regarding sporadic forms, and this may be relevant due to the future therapeutic implications of all forms of PD.
Collapse
Affiliation(s)
- Ana Vinagre-Aragón
- Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - David Campo-Caballero
- Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Elisabet Mondragón-Rezola
- Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Lara Pardina-Vilella
- Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | | | - Ana Gorostidi
- Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Ioana Croitoru
- Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Alberto Bergareche
- Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Javier Ruiz-Martinez
- Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| |
Collapse
|
7
|
Solé-Casals J, Anchustegui-Echearte I, Marti-Puig P, Calvo PM, Bergareche A, Sánchez-Méndez JI, Lopez-de-Ipina K. Discrete Cosine Transform for the Analysis of Essential Tremor. Front Physiol 2019; 9:1947. [PMID: 30705638 PMCID: PMC6345195 DOI: 10.3389/fphys.2018.01947] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Accepted: 12/22/2018] [Indexed: 01/18/2023] Open
Abstract
Essential tremor (ET) is the most common movement disorder. In fact, its prevalence is about 20 times higher than that of Parkinson's disease. In addition, studies have shown that a high percentage of cases, between 50 and 70%, are estimated to be of genetic origin. The gold standard test for diagnosis, monitoring and to differentiate between both pathologies is based on the drawing of the Archimedes' spiral. Our major challenge is to develop the simplest system able to correctly classify Archimedes' spirals, therefore we will exclusively use the information of the x and y coordinates. This is the minimum information provided by any digitizing device. We explore the use of features from drawings related to the Discrete Cosine Transform as part of a wider cross-study for the diagnosis of essential tremor held at Biodonostia. We compare the performance of these features against other classic and already analyzed ones. We outperform previous results using a very simple system and a reduced set of features. Because the system is simple, it will be possible to implement it in a portable device (microcontroller), which will receive the x and y coordinates and will issue the classification result. This can be done in real time, and therefore without needing any extra job from the medical team. In future works these new drawing-biomarkers will be integrated with the ones obtained in the previous Biodonostia study. Undoubtedly, the use of this technology and user-friendly tools based on indirect measures could provide remarkable social and economic benefits.
Collapse
Affiliation(s)
- Jordi Solé-Casals
- Data and Signal Processing Research Group, University of Vic-Central University of Catalonia, Barcelona, Spain
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
| | - Iker Anchustegui-Echearte
- Data and Signal Processing Research Group, University of Vic-Central University of Catalonia, Barcelona, Spain
- Seidor Labs, Tona, Spain
| | - Pere Marti-Puig
- Data and Signal Processing Research Group, University of Vic-Central University of Catalonia, Barcelona, Spain
| | - Pilar M. Calvo
- EleKin Research Group, System Engineering and Automation Department, University of the Basque Country UPV/EHU, Donostia, Spain
| | - Alberto Bergareche
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain
- Movement Disorders Unit, Department of Neurology, University Hospital Donostia, San Sebastián, Spain
- Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - José Ignacio Sánchez-Méndez
- EleKin Research Group, System Engineering and Automation Department, University of the Basque Country UPV/EHU, Donostia, Spain
| | - Karmele Lopez-de-Ipina
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
- EleKin Research Group, System Engineering and Automation Department, University of the Basque Country UPV/EHU, Donostia, Spain
| |
Collapse
|
8
|
Delgado-Alvarado M, Dacosta-Aguayo R, Navalpotro-Gómez I, Gago B, Gorostidi A, Jiménez-Urbieta H, Quiroga-Varela A, Ruiz-Martínez J, Bergareche A, Rodríguez-Oroz MC. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study. Mov Disord 2018; 33:1809-1813. [PMID: 30423201 DOI: 10.1002/mds.27518] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2017] [Revised: 08/10/2018] [Accepted: 08/22/2018] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND There is a need for biomarkers of dementia in PD. OBJECTIVES To determine if the levels of the main CSF proteins and their ratios are associated with deterioration in cognition and progression to dementia in the short to mid term. METHODS The Parkinson's Progression Markers Initiative database was used as an exploratory cohort, and a center-based cohort was used as a replication cohort. Amyloid ß1-42, total tau, threonine-181 phosphorylated tau, and α-synuclein in the CSF and the ratios of these proteins were assessed. RESULTS In the Parkinson's Progression Markers Initiative cohort (n = 281), the total tau/amyloid ß1-42, total tau/α-synuclein, total tau/amyloid ß1-42+α-synuclein, and amyloid ß1-42/total tau ratios were associated with a risk of progression to dementia over a 3-year follow-up. In the replication cohort (n = 40), the total tau/α-synuclein and total tau/amyloid ß1-42+α-synuclein ratios were associated with progression to dementia over a 41-month follow-up. CONCLUSION Ratios of the main proteins found in PD patient brain inclusions that can be measured in the CSF appear to have value as short- to mid-term predictors of dementia. © 2018 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Manuel Delgado-Alvarado
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Rosalía Dacosta-Aguayo
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Irene Navalpotro-Gómez
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Belén Gago
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Ana Gorostidi
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Genomics Platform, Biodonostia Research Institute, San Sebastián, Spain
| | - Haritz Jiménez-Urbieta
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Ana Quiroga-Varela
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Clinica Universidad de Navarra, Center for Applied Medical Research (CIMA)-Universidad de Navarra, Pamplona, Spain
| | - Javier Ruiz-Martínez
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Movement Disorders Unit, Department of Neurology, University Hospital Donostia, San Sebastián, Spain
| | - Alberto Bergareche
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Movement Disorders Unit, Department of Neurology, University Hospital Donostia, San Sebastián, Spain
| | - María C Rodríguez-Oroz
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.,Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.,Clinica Universidad de Navarra, Center for Applied Medical Research (CIMA)-Universidad de Navarra, Pamplona, Spain.,Movement Disorders Unit, Department of Neurology, University Hospital Donostia, San Sebastián, Spain.,Ikerbasque (Basque Foundation for Science), Bilbao, Spain.,Basque Center on Cognition Brain and Language (BCBL), San Sebastián, Spain
| |
Collapse
|
9
|
Lopez-de-Ipina K, Solé-Casals J, Faúndez-Zanuy M, Calvo PM, Sesa E, Roure J, Martinez-de-Lizarduy U, Beitia B, Fernández E, Iradi J, Garcia-Melero J, Bergareche A. Automatic Analysis of Archimedes' Spiral for Characterization of Genetic Essential Tremor Based on Shannon's Entropy and Fractal Dimension. Entropy (Basel) 2018; 20:E531. [PMID: 33265620 PMCID: PMC7513055 DOI: 10.3390/e20070531] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/20/2018] [Revised: 07/11/2018] [Accepted: 07/11/2018] [Indexed: 02/06/2023]
Abstract
Among neural disorders related to movement, essential tremor has the highest prevalence; in fact, it is twenty times more common than Parkinson's disease. The drawing of the Archimedes' spiral is the gold standard test to distinguish between both pathologies. The aim of this paper is to select non-linear biomarkers based on the analysis of digital drawings. It belongs to a larger cross study for early diagnosis of essential tremor that also includes genetic information. The proposed automatic analysis system consists in a hybrid solution: Machine Learning paradigms and automatic selection of features based on statistical tests using medical criteria. Moreover, the selected biomarkers comprise not only commonly used linear features (static and dynamic), but also other non-linear ones: Shannon entropy and Fractal Dimension. The results are hopeful, and the developed tool can easily be adapted to users; and taking into account social and economic points of view, it could be very helpful in real complex environments.
Collapse
Affiliation(s)
- Karmele Lopez-de-Ipina
- Systems Engineering and Automation Department, EleKin Research Group, University of the Basque Country UPV/EHU, 20018 Donostia, Spain
| | - Jordi Solé-Casals
- Data and Signal Processing Research Group, University of Vic—Central University of Catalonia, 08500 Barcelona, Spain
| | - Marcos Faúndez-Zanuy
- Escola Superior Politècnica Tecnocampus, Universitat Pompeu Fabra, 08002 Barcelona, Spain
| | - Pilar M. Calvo
- Systems Engineering and Automation Department, EleKin Research Group, University of the Basque Country UPV/EHU, 20018 Donostia, Spain
| | - Enric Sesa
- Escola Superior Politècnica Tecnocampus, Universitat Pompeu Fabra, 08002 Barcelona, Spain
| | - Josep Roure
- Escola Superior Politècnica Tecnocampus, Universitat Pompeu Fabra, 08002 Barcelona, Spain
| | - Unai Martinez-de-Lizarduy
- Department of Electronic Technology, EleKin Research Group, University of the Basque Country UPV/EHU, 20018 Donostia, Spain
| | - Blanca Beitia
- Department of Mathematics, EleKin Research Group, University of the Basque Country UPV/EHU, 1006 Gasteiz, Spain
| | - Elsa Fernández
- Systems Engineering and Automation Department, EleKin Research Group, University of the Basque Country UPV/EHU, 20018 Donostia, Spain
| | - Jon Iradi
- Department of Enterprises Organization, EleKin Research Group, University of the Basque Country UPV/EHU, 20018 Donostia, Spain
| | - Joseba Garcia-Melero
- Department of Mechanical Engineering, EleKin Research Group, University of the Basque Country UPV/EHU, 1006 Gasteiz, Spain
| | - Alberto Bergareche
- Department of Neuroscience, BioDonostia Health Institute, 20014 Donostia, Spain
| |
Collapse
|
10
|
Ruiz-Martínez J, Azcona LJ, Bergareche A, Martí-Massó JF, Paisán-Ruiz C. Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson disease. Neurol Genet 2017; 3:e177. [PMID: 28808687 PMCID: PMC5540655 DOI: 10.1212/nxg.0000000000000177] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Accepted: 06/16/2017] [Indexed: 12/26/2022]
Abstract
OBJECTIVE Despite the enormous advancements made in deciphering the genetic architecture of Parkinson disease (PD), the majority of PD is idiopathic, with single gene mutations explaining only a small proportion of the cases. METHODS In this study, we clinically evaluated 2 unrelated Spanish families diagnosed with PD, in which known PD genes were previously excluded, and performed whole-exome sequencing analyses in affected individuals for disease gene identification. RESULTS Patients were diagnosed with typical PD without relevant distinctive symptoms. Two different novel mutations were identified in the CSMD1 gene. The CSMD1 gene, which encodes a complement control protein that is known to participate in the complement activation and inflammation in the developing CNS, was previously shown to be associated with the risk of PD in a genome-wide association study. CONCLUSIONS We conclude that the CSMD1 mutations identified in this study might be responsible for the PD phenotype observed in our examined patients. This, along with previous reported studies, may suggest the complement pathway as an important therapeutic target for PD and other neurodegenerative diseases.
Collapse
Affiliation(s)
- Javier Ruiz-Martínez
- Department of Neurology (J.R.-M., A.B., J.F.M.-M.), University Hospital Donostia, San Sebastián, Spain; Neurosciences Area, Biodonostia Research Institute (J.R.-M., A.B., J.F.M.-M.), San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED) (J.R.-M., A.B., J.F.M.-M.), Madrid, Spain; Department of Neuroscience (L.J.A.), Departments of Neurology, Psychiatry, and Genetics and Genomic Sciences (C.P.-R.), Friedman Brain and Mindich Child Health and Development Institutes (C.P.-R.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Neuroscience (J.F.M.-M.), University of the Basque Country-UPV-EHU, San Sebastián, Spain
| | - Luis J Azcona
- Department of Neurology (J.R.-M., A.B., J.F.M.-M.), University Hospital Donostia, San Sebastián, Spain; Neurosciences Area, Biodonostia Research Institute (J.R.-M., A.B., J.F.M.-M.), San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED) (J.R.-M., A.B., J.F.M.-M.), Madrid, Spain; Department of Neuroscience (L.J.A.), Departments of Neurology, Psychiatry, and Genetics and Genomic Sciences (C.P.-R.), Friedman Brain and Mindich Child Health and Development Institutes (C.P.-R.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Neuroscience (J.F.M.-M.), University of the Basque Country-UPV-EHU, San Sebastián, Spain
| | - Alberto Bergareche
- Department of Neurology (J.R.-M., A.B., J.F.M.-M.), University Hospital Donostia, San Sebastián, Spain; Neurosciences Area, Biodonostia Research Institute (J.R.-M., A.B., J.F.M.-M.), San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED) (J.R.-M., A.B., J.F.M.-M.), Madrid, Spain; Department of Neuroscience (L.J.A.), Departments of Neurology, Psychiatry, and Genetics and Genomic Sciences (C.P.-R.), Friedman Brain and Mindich Child Health and Development Institutes (C.P.-R.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Neuroscience (J.F.M.-M.), University of the Basque Country-UPV-EHU, San Sebastián, Spain
| | - Jose F Martí-Massó
- Department of Neurology (J.R.-M., A.B., J.F.M.-M.), University Hospital Donostia, San Sebastián, Spain; Neurosciences Area, Biodonostia Research Institute (J.R.-M., A.B., J.F.M.-M.), San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED) (J.R.-M., A.B., J.F.M.-M.), Madrid, Spain; Department of Neuroscience (L.J.A.), Departments of Neurology, Psychiatry, and Genetics and Genomic Sciences (C.P.-R.), Friedman Brain and Mindich Child Health and Development Institutes (C.P.-R.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Neuroscience (J.F.M.-M.), University of the Basque Country-UPV-EHU, San Sebastián, Spain
| | - Coro Paisán-Ruiz
- Department of Neurology (J.R.-M., A.B., J.F.M.-M.), University Hospital Donostia, San Sebastián, Spain; Neurosciences Area, Biodonostia Research Institute (J.R.-M., A.B., J.F.M.-M.), San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED) (J.R.-M., A.B., J.F.M.-M.), Madrid, Spain; Department of Neuroscience (L.J.A.), Departments of Neurology, Psychiatry, and Genetics and Genomic Sciences (C.P.-R.), Friedman Brain and Mindich Child Health and Development Institutes (C.P.-R.), Icahn School of Medicine at Mount Sinai, New York, NY; and Department of Neuroscience (J.F.M.-M.), University of the Basque Country-UPV-EHU, San Sebastián, Spain
| |
Collapse
|
11
|
Gorostidi A, Martí-Massó JF, Bergareche A, Rodríguez-Oroz MC, López de Munain A, Ruiz-Martínez J. Genetic Mutation Analysis of Parkinson's Disease Patients Using Multigene Next-Generation Sequencing Panels. Mol Diagn Ther 2017; 20:481-91. [PMID: 27294386 DOI: 10.1007/s40291-016-0216-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting millions of people. Genome-wide association studies (GWAS) have found >25 genetic risk factors and at least 15 loci directly associated with PD. Recent advances in new next-generation DNA sequencing technologies, such as the semiconductor-based Ion Torrent platform, make multigene sequencing cheaper, faster, and more reliable. OBJECTIVES Our objective was to test the power of this next-generation sequencing technology to analyze large samples by screening the majority of the most relevant PD-related genes known for single and compound mutations. METHODS To archive a rapid, robust, and cost-effective genetic analysis of a PD cohort, we designed a multiplex, polymerase chain reaction (PCR)-based primer panel to amplify and sequence coding exons of 15 PD-associated genes (SNCA, LRRK2, PARK2, PINK1, PARK7, GIGYF2, ATP13A2, UCHL1, PLA2G6, FBXO7, EIF4G1, VPS35, ACMSD, APOE, and GBA). We conducted parallel sequencing using the Ion Torrent Personal Genome Machine(®) system to detect mutations in 92 blood DNA samples from PD patients. RESULTS After bioinformatics analysis and filtering, 95.13 % coverage of the targeted region was obtained at >40-fold mean coverage. The results revealed 44 previously documented variants in these 15 genes, with five revealed as pathogenic. We also discovered six novel variants, five of which had an in silico prediction of being pathogenic. CONCLUSIONS Benchtop next-generation sequencing is a powerful method for genetic screening for PD. Our results indicated that it yielded a high frequency of discovery (66 %; n = 92) of variants in carriers from an enriched Spanish PD sample.
Collapse
Affiliation(s)
- Ana Gorostidi
- Genomics Platform, Biodonostia Research Institute, Dr. Begiristain s/n, San Sebastian, 20014, Gipuzkoa, Spain.
- Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain.
| | - José Félix Martí-Massó
- Neurology Service, Hospital Universitario Donostia, San Sebastian, Spain
- Ilundain Fundazioa, San Sebastian, Spain
- Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain
- Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Spain
| | - Alberto Bergareche
- Neurology Service, Hospital Universitario Donostia, San Sebastian, Spain
- Ilundain Fundazioa, San Sebastian, Spain
- Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain
| | - Mari Cruz Rodríguez-Oroz
- Neurology Service, Hospital Universitario Donostia, San Sebastian, Spain
- Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain
- Ikerbasque. Basque Foundation for Science, Bilbao, Spain
| | - Adolfo López de Munain
- Neurology Service, Hospital Universitario Donostia, San Sebastian, Spain
- Ilundain Fundazioa, San Sebastian, Spain
- Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain
- Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Spain
| | - Javier Ruiz-Martínez
- Neurology Service, Hospital Universitario Donostia, San Sebastian, Spain
- Ilundain Fundazioa, San Sebastian, Spain
- Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain
| |
Collapse
|
12
|
Delgado-Alvarado M, Gago B, Gorostidi A, Jiménez-Urbieta H, Dacosta-Aguayo R, Navalpotro-Gómez I, Ruiz-Martínez J, Bergareche A, Martí-Massó JF, Martínez-Lage P, Izagirre A, Rodríguez-Oroz MC. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Mov Disord 2017; 32:1066-1073. [DOI: 10.1002/mds.27001] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 03/01/2017] [Accepted: 03/03/2017] [Indexed: 01/13/2023] Open
Affiliation(s)
- Manuel Delgado-Alvarado
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| | - Belén Gago
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| | - Ana Gorostidi
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Genomics Platform, Biodonostia Research Institute; San Sebastián Spain
| | - Haritz Jiménez-Urbieta
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| | - Rosalía Dacosta-Aguayo
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| | - Irene Navalpotro-Gómez
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
| | - Javier Ruiz-Martínez
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Movement Disorders Unit, Department of Neurology, University Hospital Donostia; San Sebastián Spain
| | - Alberto Bergareche
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Movement Disorders Unit, Department of Neurology, University Hospital Donostia; San Sebastián Spain
| | - José F. Martí-Massó
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Movement Disorders Unit, Department of Neurology, University Hospital Donostia; San Sebastián Spain
| | | | - Andrea Izagirre
- Department of Neurology, CITA-Alzheimer Foundation; San Sebastián Spain
| | - María C. Rodríguez-Oroz
- Neurodegenerative Disorders Area, Biodonostia Health Research Institute; San Sebastián Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Madrid Spain
- Movement Disorders Unit, Department of Neurology, University Hospital Donostia; San Sebastián Spain
- Ikerbasque (Basque Foundation for Science); Bilbao Spain
- Basque Center on Cognition Brain and Language (BCBL); San Sebastián Spain
| |
Collapse
|
13
|
Virues-Ortega J, Vega S, Seijo-Martinez M, Saz P, Rodriguez F, Rodriguez-Laso A, de Las Heras SP, Mateos R, Martinez-Martin P, Mahillo-Fernandez I, Garre-Olmo J, Gascon J, Garcia-Garcia FJ, Fernandez-Martinez M, Bermejo-Pareja F, Bergareche A, Benito-Leon J, de Pedro-Cuesta J. A protective personal factor against disability and dependence in the elderly: an ordinal regression analysis with nine geographically-defined samples from Spain. BMC Geriatr 2017; 17:42. [PMID: 28143509 PMCID: PMC5286674 DOI: 10.1186/s12877-016-0409-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Accepted: 12/31/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Sense of Coherence (SOC) is defined as a tendency to perceive life experiences as comprehensible, manageable and meaningful. The construct is split in three major domains: Comprehensibility, Manageability, and Meaningfulness. SOC has been associated with successful coping strategies in the face of illness and traumatic events and is a predictor of self-reported and objective health in a variety of contexts. In the present study we aim to evaluate the association of SOC with disability and dependence in Spanish elders. METHODS A total of 377 participants aged 75 years or over from nine locations across Spain participated in the study (Mean age: 80.9 years; 65.3% women). SOC levels were considered independent variables in two ordinal logistic models on disability and dependence, respectively. Disability was established with the World health Organization-Disability Assessment Schedule 2.0 (36-item version), while dependence was measured with the Extended Katz Index on personal and instrumental activities of daily living. The models included personal (sex, age, social contacts, availability of an intimate confidant), environmental (municipality size, access to social resources) and health-related covariates (morbidity). RESULTS High Meaningfulness was a strong protective factor against both disability (Odds Ratio [OR] = 0.50; 95% Confidence Interval [CI] = 0.29-0.87) and dependence (OR = 0.33; 95% CI = 0.19-0.58) while moderate and high Comprehensibility was protective for disability (OR = 0.40; 95% CI = 0.22-0.70 and OR = 0.39; 95%CI = 0.21-0.74), but not for dependence. Easy access to social and health resources was also highly protective against both disability and dependence. CONCLUSIONS Our results are consistent with the view that high levels of SOC are protective against disability and dependence in the elderly. Elderly individuals with limited access to social and health resources and with low SOC may be a group at risk for dependence and disability in Spain.
Collapse
Affiliation(s)
- Javier Virues-Ortega
- National Centre for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain. .,School of Psychology, The University of Auckland, Room 335B Level 3 Bldg 301 Science Centre 23 Symonds St Private Bag 92019, Auckland, 1010, New Zealand.
| | | | | | - Pedro Saz
- Department of Medicine and Psychiatry, Zaragoza University, Zaragoza, Spain
| | | | | | | | - Raimundo Mateos
- Psychiatry Department, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Pablo Martinez-Martin
- National Centre for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain
| | | | - Josep Garre-Olmo
- Girona Biomedical Research Institute Institut d'Assistència Sanitària, Salt, Spain
| | - Jordi Gascon
- Dementia Diagnosis and Treatment Unit, Neurology Department, Bellvitge University Teaching Hospital, Barcelona, Spain
| | | | | | - Felix Bermejo-Pareja
- Neurology Department, 12 de Octubre University Teaching Hospital and CIBERNED, Madrid, Spain
| | - Alberto Bergareche
- Department of Neurology, Hospital Universitario Donostia, San Sebastián Guipuzcoa, Spain.,Biodonostia Research Institute, Area of Neurosciences, and CIBERNED, Carlos III Health Institute, Madrid, Spain
| | - Julian Benito-Leon
- Neurology Department, 12 de Octubre University Teaching Hospital and CIBERNED, Madrid, Spain
| | - Jesus de Pedro-Cuesta
- National Centre for Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain
| | | |
Collapse
|
14
|
Bergareche A, Bednarz MJ, Sánchez E, Krebs CE, Ruiz-Martinez J, De la Riva P, Makarov V, Gorostidi A, Jurkat-Rott K, Marti-Masso JF, Paisán-Ruiz C. SCN4A Pore Mutation Pathogenetically Contributes to Autosomal Dominant Essential Tremor and May Increase Susceptibility to Epilepsy. Biophys J 2016. [DOI: 10.1016/j.bpj.2015.11.657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
15
|
Bergareche A, Rodríguez-Oroz MC, Estanga A, Gorostidi A, López de Munain A, Castillo-Triviño T, Ruiz-Martínez J, Mondragón E, Gaig C, Lomeña F, Sarasqueta C, Tolosa E, Martí-Massó JF. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease. Mov Disord 2015; 31:335-43. [DOI: 10.1002/mds.26478] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 10/08/2015] [Accepted: 10/11/2015] [Indexed: 12/25/2022] Open
Affiliation(s)
- Alberto Bergareche
- Neurology Service; Hospital Universitario Donostia; San Sebastian Spain
- Ilundain Fundazioa; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
| | - Maria Cruz Rodríguez-Oroz
- Neurology Service; Hospital Universitario Donostia; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
- Ikerbasque. Basque Foundation for Science; Bilbao Spain
| | - Ainara Estanga
- Ilundain Fundazioa; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
- Department of Neuroscience; University of the Basque Country UPV/EHU; Spain
| | - Ana Gorostidi
- Neuroscience Area. Biodonostia Research Institute; Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
| | - Adolfo López de Munain
- Neurology Service; Hospital Universitario Donostia; San Sebastian Spain
- Ilundain Fundazioa; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
- Department of Neuroscience; University of the Basque Country UPV/EHU; Spain
| | - Tamara Castillo-Triviño
- Neurology Service; Hospital Universitario Donostia; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
| | - Javier Ruiz-Martínez
- Neurology Service; Hospital Universitario Donostia; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
| | - Elisabet Mondragón
- Neurology Service; Hospital Universitario Donostia; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
| | - Carles Gaig
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
- Neurology Service, Multidisciplinary Sleep Unit, Hospital Clínic and Institut d'Investigació Biomèdiques August Pi i Sunyer; Spain
| | - Francisco Lomeña
- Nuclear Medicine Service, Hospital Clinic de Barcelona, Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Hospital Clinic de Barcelona; Spain
| | - Cristina Sarasqueta
- Unidad de Apoyo Metodológico. Hospital Universitario Donostia. Biodonostia Research Institute, REDISSEC; Spain
| | - Eduardo Tolosa
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
- Neurology Service, Hospital Clinic de Barcelona, IDIBAPS; Spain
| | - José Félix Martí-Massó
- Neurology Service; Hospital Universitario Donostia; San Sebastian Spain
- Ilundain Fundazioa; San Sebastian Spain
- Neuroscience Area. Biodonostia Research Institute; Spain
- Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness; Spain
- Department of Neuroscience; University of the Basque Country UPV/EHU; Spain
| |
Collapse
|
16
|
Bergareche A, Bednarz M, Sánchez E, Krebs CE, Ruiz-Martinez J, De La Riva P, Makarov V, Gorostidi A, Jurkat-Rott K, Marti-Masso JF, Paisán-Ruiz C. SCN4A pore mutation pathogenetically contributes to autosomal dominant essential tremor and may increase susceptibility to epilepsy. Hum Mol Genet 2015; 24:7111-20. [PMID: 26427606 DOI: 10.1093/hmg/ddv410] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 09/25/2015] [Indexed: 12/19/2022] Open
Abstract
Essential tremor (ET) is the most prevalent movement disorder, affecting millions of people in the USA. Although a positive family history is one of the most important risk factors for ET, the genetic causes of ET remain unknown. In an attempt to identify genetic causes for ET, we performed whole-exome sequencing analyses in a large Spanish family with ET, in which two patients also developed epilepsy. To further assess pathogenicity, site-directed mutagenesis, mouse and human brain expression analyses, and patch clamp techniques were performed. A disease-segregating mutation (p.Gly1537Ser) in the SCN4A gene was identified. Posterior functional analyses demonstrated that more rapid kinetics at near-threshold potentials altered ion selectivity and facilitated the conductance of both potassium and ammonium ions, which could contribute to tremor and increase susceptibility to epilepsy, respectively. In this report, for the first time, we associated the genetic variability of SCN4A with the development of essential tremor, which adds ET to the growing list of neurological channelopathies.
Collapse
Affiliation(s)
- Alberto Bergareche
- Movement Disorders Unit, Department of Neurology Hospital Universitario Donostia San Sebastián Guipuzcoa Spain, Biodonostia Research Institute, Area of Neurosciences, Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Marcin Bednarz
- Division of Neurophysiology, Ulm University, Albert-Einstein-Allee 11, 89070 Ulm, Germany
| | | | | | - Javier Ruiz-Martinez
- Movement Disorders Unit, Department of Neurology Hospital Universitario Donostia San Sebastián Guipuzcoa Spain, Biodonostia Research Institute, Area of Neurosciences, Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Patricia De La Riva
- Movement Disorders Unit, Department of Neurology Hospital Universitario Donostia San Sebastián Guipuzcoa Spain, Biodonostia Research Institute, Area of Neurosciences, Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Vladimir Makarov
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
| | - Ana Gorostidi
- Movement Disorders Unit, Department of Neurology Hospital Universitario Donostia San Sebastián Guipuzcoa Spain, Biodonostia Research Institute, Area of Neurosciences, Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Karin Jurkat-Rott
- Division of Neurophysiology, Ulm University, Albert-Einstein-Allee 11, 89070 Ulm, Germany
| | - Jose Felix Marti-Masso
- Movement Disorders Unit, Department of Neurology Hospital Universitario Donostia San Sebastián Guipuzcoa Spain, Biodonostia Research Institute, Area of Neurosciences, Department of Neurosciences University of the Basque Country, EHU-UPV San Sebastián Gipuzkoa Spain, Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Coro Paisán-Ruiz
- Department of Neurology, Department of Psychiatry, Department of Genetics and Genomic Sciences, Friedman Brain Institute, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA and
| |
Collapse
|
17
|
Gallo V, Brayne C, Forsgren L, Barker RA, Petersson J, Hansson O, Lindqvist D, Ruffmann C, Ishihara L, Luben R, Arriola L, Bergareche A, Gavrila D, Erro ME, Vanacore N, Sacerdote C, Bueno-de-Mesquita B, Vermeulen R, Seelen M, Sieri S, Masala G, Ramat S, Kyrozis A, Thricopolou A, Panico S, Mattiello A, Kaaks R, Teucher B, Katzke V, Kloss M, Curry L, Calboli F, Riboli E, Vineis P, Middleton L. Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. NEURODEGENER DIS 2015; 15:331-8. [PMID: 26375921 DOI: 10.1159/000381857] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Accepted: 03/19/2015] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS Large epidemiological prospective studies represent an important opportunity for investigating risk factors for rare diseases such as Parkinson's disease (PD). Here we describe the procedures we used for ascertaining PD cases in the EPIC (European Prospective Investigation into Cancer and Nutrition) study. METHODS The following three-phase procedure was used: (1) elaboration of a NeuroEPIC4PD template for clinical data collection, (2) identification of all potential PD cases via record linkage and (3) validation of the diagnosis through clinical record revision, in a population of 220,494 subjects recruited in 7 European countries. All cases were labelled with the NeuroEPIC4PD diagnoses of 'definite', 'very likely', 'probable', or 'possible' PD. RESULTS A total of 881 PD cases were identified, with over 2,741,780 person-years of follow-up (199 definite, 275 very likely, 146 probable, and 261 possible). Of these, 734 were incident cases. The mean age at diagnosis was 67.9 years (SD 9.2) and 458 patients (52.0%) were men. Bradykinesia was the most frequent presenting motor sign (76.5%). Tremor-dominant and akinetic rigid forms of PD were the most common types of PD. A total of 289 patients (32.8%) were dead at the time of the last follow-up. CONCLUSIONS This exercise proved that it is feasible to ascertain PD in large population-based cohort studies and offers a potential framework to be replicated in similar studies.
Collapse
Affiliation(s)
- Valentina Gallo
- School of Public Health, Imperial College London, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Sánchez E, Bergareche A, Krebs CE, Gorostidi A, Makarov V, Ruiz-Martinez J, Chorny A, Lopez de Munain A, Marti-Masso JF, Paisán-Ruiz C. SORT1 Mutation Resulting in Sortilin Deficiency and p75(NTR) Upregulation in a Family With Essential Tremor. ASN Neuro 2015; 7:7/4/1759091415598290. [PMID: 26297037 PMCID: PMC4550298 DOI: 10.1177/1759091415598290] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
*These authors contributed equally to this work. Essential tremor (ET) is the most prevalent movement disorder affecting millions of people in the United States. Although a positive family history is one of the most important risk factors for ET, the genetic causes of ET remain unknown. In this study, whole exome sequencing and subsequent approaches were performed in a family with an autosomal dominant form of early-onset ET. Functional analyses including mutagenesis, cell culture, gene expression, enzyme-linked immunosorbent, and apoptosis assays were also performed. A disease-segregating mutation (p.Gly171Ala), absent in normal population, was identified in the SORT1 gene. The p.Gly171Ala mutation was shown not only to impair the expression of its encoding protein sortilin but also the mRNA levels of its binding partner p75 neurotrophin receptor that is known to be implicated in brain injury, neuronal apoptosis, and neurotransmission.
Collapse
Affiliation(s)
- Elena Sánchez
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Alberto Bergareche
- Biodonostia Research Institute, University of the Basque Country, San Sebastián, Gipuzkoa, Spain Department of Neurology, Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Catharine E Krebs
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ana Gorostidi
- Biodonostia Research Institute, University of the Basque Country, San Sebastián, Gipuzkoa, Spain Department of Neurology, Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | | | - Javier Ruiz-Martinez
- Biodonostia Research Institute, University of the Basque Country, San Sebastián, Gipuzkoa, Spain Department of Neurology, Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Alejo Chorny
- Department of Medicine, The Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Adolfo Lopez de Munain
- Biodonostia Research Institute, University of the Basque Country, San Sebastián, Gipuzkoa, Spain Department of Neurology, Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain Department of Neurosciences, University of the Basque Country, San Sebastián, Guipuzcoa, Spain
| | - Jose Felix Marti-Masso
- Biodonostia Research Institute, University of the Basque Country, San Sebastián, Gipuzkoa, Spain Department of Neurology, Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain Department of Neurosciences, University of the Basque Country, San Sebastián, Guipuzcoa, Spain
| | - Coro Paisán-Ruiz
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Departments of Psychiatry and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA Friedman Brain and Mindich Child Health and Development Institutes, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
19
|
Estanga A, Rodriguez-Oroz MC, Ruiz-Martinez J, Barandiaran M, Gorostidi A, Bergareche A, Mondragon E, Lopez de Munain A, Marti-Masso JF. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2. Parkinsonism Relat Disord 2014; 20:1097-100. [PMID: 25127457 DOI: 10.1016/j.parkreldis.2014.07.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Revised: 06/23/2014] [Accepted: 07/09/2014] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The neuropsychological characteristics of patients with Parkinson's Disease (PD) associated with R1441G mutation in the LRRK2 gene (R1441G-PD) are not well known. The aim of this study was to examine the cognitive status and mood of R1441G-PD patients. METHODS Thirty patients with R1441G-PD were compared with thirty idiopathic PD (i-PD) patients who were matched by age, sex, education, disease onset age and duration, using a comprehensive battery of neuropsychological test, and considering the Movement Disorder Society (MDS) criteria for the diagnosis of Mild Cognitive Impairment (PD-MCI) and dementia (PD-Dementia). RESULTS The mean scores in the depression and anxiety scales were similar in the two groups. Depressive symptoms were detected in 31.8% of R1441G-PD and 25% of i-PD patients and anxiety symptoms were evident in 4.5% and 15%, respectively, but the differences were not significant. The only neuropsychological test on which there was a significantly worse performance in the R1441G-PD group was the Boston naming test but the difference became not significant when Bonferroni's correction was applied. The prevalence of PD-MCI was 30% in both R1441G-PD and i-PD, with no differences in the number and type of domains altered given that executive function, memory and attention were mainly affected. PD-Dementia was diagnosed in 13.3% (n = 4) of R1441G-PD and 26.7% (n = 8) of i-PD patients (difference was not significant). CONCLUSION In conclusion, significant differences were not detected between R1441G-PD and i-PD in cognitive, depression and anxiety scales, or PD-MCI and PD-Dementia prevalence, and the cognitive profile was identical in the two groups.
Collapse
Affiliation(s)
- A Estanga
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neuroscience, University of the Basque Country UPV/EHU, Spain.
| | - M C Rodriguez-Oroz
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain
| | - J Ruiz-Martinez
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain
| | - M Barandiaran
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain
| | - A Gorostidi
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain
| | - A Bergareche
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain
| | - E Mondragon
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain
| | - A Lopez de Munain
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain; Department of Neuroscience, University of the Basque Country UPV/EHU, Spain
| | - J F Marti-Masso
- Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain; Department of Neuroscience, University of the Basque Country UPV/EHU, Spain
| |
Collapse
|
20
|
Ruiz-Martínez J, de la Riva P, Rodríguez-Oroz MC, Mondragón Rezola E, Bergareche A, Gorostidi A, Gago B, Estanga A, Larrañaga N, Sarasqueta C, López de Munain A, Martí Massó JF. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2. Mov Disord 2013; 29:750-5. [PMID: 24357540 DOI: 10.1002/mds.25778] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 10/01/2013] [Accepted: 10/07/2013] [Indexed: 11/08/2022] Open
Abstract
An inverse relationship between Parkinson's disease (PD) and cancer has been described. However, the association between cancers and genetic forms of PD, in particular the R1441G mutation in the LRRK2 gene, is not well known. The objective of this work was to analyze cancer prevalence in PD patients with R1441G or G2019S mutations in LRRK2, and in idiopathic PD (iPD). A total of 732 patients with PD (70 and 25 carriers of R1441G or G2019S mutations, respectively), and 177 controls, were linked using a population-based cancer registry of the Spanish province of Gipuzkoa. Cancer prevalence was not significantly higher in PD-G2019S carriers (20%) than in PD-R1441G carriers (14.3%), iPD (13.8%), or controls (12.5%). With the exception of a high prevalence of hematological cancers (crude odds ratio of 7.1) in the R1441G group, specific cancer types were not increased in PD mutation carriers. In both the carrier and iPD groups, cancers were diagnosed after the onset of PD. PD patients had a similar prevalence of cancer to control subjects. There was no increased association between G2019S or R1441G mutations and any type of cancer. Although there was a higher prevalence of hematological cancers in the R1441G group, the low number of such cancers overall makes this finding of uncertain significance. There was a slightly higher but not statistically significant prevalence of non-skin cancers in the G2019S group, suggesting that further study to evaluate the association should be undertaken prior to ascribing an increased cancer risk to this population.
Collapse
Affiliation(s)
- Javier Ruiz-Martínez
- Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain; Neurosciences Area, Biodonostia Institute, San Sebastián, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Lewy bodies are the hallmark of Parkinson disease and their sophisticated analysis will undoubtedly elucidate the pathogenic process. They have been studied by using different microscopic tools. The authors have used atomic force microscopy (AFM) to study the ultramicrotom cut postmortem brain tissue of Parkinson disease patients. Under the same preparation conditions, they have found aggregated fibrillary nanostructures in Lewy bodies, as well as a loss of connections between neurons located in other parts of the substantia nigra. Although these results are preliminary and descriptive in nature, this paper reports the application of a novel and intriguing technique. Further studies including the study of cortical LB and Lewy neurites will be needed to determine the full potential of AFM in the study of the pathogenesis of cell death in Parkinson disease and other synucleinopathies.
Collapse
Affiliation(s)
- Agnieszka Tercjak
- Department of Chemical and Environmental Engineering, University of the Basque Country , Spain
| | | | | | | | | |
Collapse
|
22
|
Martí-Massó JF, Bergareche A, Makarov V, Ruiz-Martinez J, Gorostidi A, López de Munain A, Poza JJ, Striano P, Buxbaum JD, Paisán-Ruiz C. The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism. J Mol Med (Berl) 2013; 91:1399-406. [PMID: 23955123 DOI: 10.1007/s00109-013-1075-4] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Revised: 07/02/2013] [Accepted: 07/29/2013] [Indexed: 11/24/2022]
Abstract
UNLABELLED Familial cortical myoclonic tremor and epilepsy is a phenotypically and genetically heterogeneous autosomal dominant disorder characterized by the presence of cortical myoclonic tremor and epilepsy that is often accompanied by additional neurological features. Despite the numerous familial studies performed and the number of loci identified, there is no gene associated with this syndrome. It is expected that through the application of novel genomic technologies, such as whole exome sequencing and whole genome sequencing, a substantial number of novel genes will come to light in the coming years. In this study, we describe the identification of two disease-segregating mutations in a large family featuring cortical myoclonic tremor with epilepsy and parkinsonism. Due to the previous association of ACMSD deficiency with the development of epileptic seizures, we concluded that the identified nonsense mutation in the ACMSD gene, which encodes for a critical enzyme of the kynurenine pathway of the tryptophan metabolism, is the disease-segregating mutation most likely to be responsible for the phenotype described in our family. This finding not only reveals the identification of the first gene associated with familial cortical myoclonic tremor and epilepsy but also discloses the kynurenine pathway as a potential therapeutic target for the treatment of this devastating syndrome. KEY MESSAGE ACMSD is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism. ACMSD mutation contributes to the development of FCMTE QA accumulation is likely to play an important role in the pathogenesis of FCMTE. The kynurenine pathway as a potential drug target for the treatment of epilepsy.
Collapse
Affiliation(s)
- Jose Felix Martí-Massó
- Biodonostia Research Institute, Neurosciences area, University of the Basque Country, EHU-UPV, San Sebastian, Gipuzkoa, Spain,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Gorostidi A, Bergareche A, Ruiz-Martínez J, Martí-Massó JF, Cruz M, Varghese S, Qureshi MM, Alzahmi F, Al-Hayani A, de Munáin AL, El-Agnaf OM. Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One 2012; 7:e52312. [PMID: 23300640 PMCID: PMC3531490 DOI: 10.1371/journal.pone.0052312] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 11/16/2012] [Indexed: 12/03/2022] Open
Abstract
The diagnosis of Parkinson's disease (PD) remains primarily a clinical issue, based mainly on phenotypic patterns. The identification of biomarkers capable of permitting the preclinical detection of PD is critically needed. α-Synuclein is a key protein in PD, with missense and multiplication mutations in the gene encoding α-synuclein (SNCA) having been reported in familial cases of PD, and accumulation of the protein identified in Lewy bodies (LBs) and Lewy neurites (LNs) in affected brain regions. With the objective of validating the use of α-synuclein as a clinical or progressive biomarker in an accessible tissue, we used an enzyme-linked immunosorbent assay (ELISA) to measure α-synuclein levels in the peripheral blood plasma of idiopathic PD and LRRK2 mutation carrier patients and compared our findings with healthy control subjects. Compared to healthy controls, we found a significant decrease in plasma total α-synuclein levels in idiopathic PD (iPD) patients (n = 134, p = 0.010). However, the reduction was less significant in patients who were LRRK2 mutation carriers (n = 32, p = 0.133). This lack of significance could be due to the small number of individuals employed in this group. No predictive value of total α-synuclein in the diagnosis of PD was found in a receiver operating characteristic (ROC) curve analysis. Although this is a pilot study requiring corroboration on a larger cohort of patients, our results highlight the possible use of plasma α-synuclein as a biomarker for PD.
Collapse
Affiliation(s)
- Ana Gorostidi
- Biodonostia Research Institute, Neurosciences area, Donostia, Gipuzkoa, Spain
- Hospital Donostia, Department of Neurology, Movement Disorders Unit, Donostia, Gipuzkoa, Spain
- Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Alberto Bergareche
- Biodonostia Research Institute, Neurosciences area, Donostia, Gipuzkoa, Spain
- Hospital Donostia, Department of Neurology, Movement Disorders Unit, Donostia, Gipuzkoa, Spain
- Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Javier Ruiz-Martínez
- Biodonostia Research Institute, Neurosciences area, Donostia, Gipuzkoa, Spain
- Hospital Donostia, Department of Neurology, Movement Disorders Unit, Donostia, Gipuzkoa, Spain
- Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - José F. Martí-Massó
- Biodonostia Research Institute, Neurosciences area, Donostia, Gipuzkoa, Spain
- Hospital Donostia, Department of Neurology, Movement Disorders Unit, Donostia, Gipuzkoa, Spain
- Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - María Cruz
- Biodonostia Research Institute, Neurosciences area, Donostia, Gipuzkoa, Spain
- Hospital Donostia, Department of Neurology, Movement Disorders Unit, Donostia, Gipuzkoa, Spain
- Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
- Ikerbasque Basque Fundation for Science, Bilbao, Bizkaia, Spain
| | - Shiji Varghese
- Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Mohamed M. Qureshi
- Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Fatimah Alzahmi
- Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Abdulmonem Al-Hayani
- Department of Anatomy, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Adolfo López de Munáin
- Biodonostia Research Institute, Neurosciences area, Donostia, Gipuzkoa, Spain
- Hospital Donostia, Department of Neurology, Movement Disorders Unit, Donostia, Gipuzkoa, Spain
- Centro de investigación biomédica en Red para enfermedades Neurodegenerativas (CIBERNED), Carlos III Health Institute, Madrid, Spain
| | - Omar M.A. El-Agnaf
- Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
- Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
24
|
Virués-Ortega J, de Pedro-Cuesta J, del Barrio JL, Almazan-Isla J, Bergareche A, Bermejo-Pareja F, Fernández-Mayoralas G, García FJ, Garre-Olmo J, Gascon-Bayarri J, Mahillo I, Martínez-Martín P, Mateos R, Rodríguez F, Rojo-Pérez F, Avellanal F, Saz P, Seijo-Martínez M. Medical, environmental and personal factors of disability in the elderly in Spain: a screening survey based on the International Classification of Functioning. Gac Sanit 2011; 25 Suppl 2:29-38. [PMID: 22088902 DOI: 10.1016/j.gaceta.2011.07.021] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2011] [Revised: 07/14/2011] [Accepted: 07/19/2011] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The International Classification of Functioning, Disability and Health (ICF) advocates a multifactorial and multifaceted conceptualization of disability. The objective of this study was to ascertain major medical, environmental and personal determinants of severe/extreme disability among the elderly population in Spain. The assessment scheme was consistent with the ICF model of disability. METHODS Nine populations contributed probabilistic or geographically-defined samples following a two-phase screening design. The Mini-Mental State Examination and the 12-item version of the World Health Organization-Disability Assessment Schedule, 2(nd) ed. (WHO-DAS II), were used as cognitive and disability screening tools, respectively. Positively screened individuals underwent clinical work-up for dementia and were administered the 36-item version of the WHO-DAS II to estimate ICF disability levels. We used logistic regression for the purposes of data combination, adjusted for age and sex in all analyses. RESULTS The sample was composed of 503 participants aged ≥ 75 years. Alzheimeŕs disease and depression were highly predictive of severe/extreme disability (OR: 17.40, 3.71). Good access to social services was strongly associated with a low level or absence of disability (OR: 0.05 to 0.18). Very difficult access to services and having dementia or another psychiatric disorder were associated with an increase in disability (OR: 66.06). There was also a significant interaction effect between access to services and neurological disorders (OR: 12.74). CONCLUSIONS Disability is highly prevalent among the Spanish elderly and is influenced by medical, social and personal factors. Disability could potentially be reduced by ensuring access to social services, preventing dementia and stroke, and treating depression.
Collapse
Affiliation(s)
- Javier Virués-Ortega
- CIBER de Enfermedades Neurodegenerativas Carlos III Institute of Health, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Martí Massó JF, Ruiz-Martínez J, Bergareche A, López de Munain A. [Parkinsonism induced by sulpiride and veralipride: two different stories]. Med Clin (Barc) 2011; 137:473-4. [PMID: 21295788 DOI: 10.1016/j.medcli.2010.09.038] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2010] [Revised: 09/17/2010] [Accepted: 09/21/2010] [Indexed: 11/19/2022]
|
26
|
Ruiz-Martínez J, Gorostidi A, Goyenechea E, Alzualde A, Poza JJ, Rodríguez F, Bergareche A, Moreno F, López de Munain A, Martí Massó JF. Olfactory deficits and cardiac 123
I-MIBG in Parkinson's disease related to the LRRK2
R1441G and G2019S mutations. Mov Disord 2011; 26:2026-31. [DOI: 10.1002/mds.23773] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2010] [Revised: 03/17/2011] [Accepted: 04/04/2011] [Indexed: 11/11/2022] Open
|
27
|
Virués-Ortega J, de Pedro-Cuesta J, Vega S, Seijo-Martínez M, Saz P, Rodríguez F, Rodríguez-Laso A, Reñé R, de Las Heras SP, Mateos R, Martínez-Martín P, Mahillo-Fernández I, López-Pousa S, Lobo A, Reglà JL, Gascón J, García FJ, Fernández-Martínez M, Boix R, Bermejo-Pareja F, Bergareche A, Sánchez-Sánchez F, de Arce A, del Barrio JL. Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain. Acta Neurol Scand 2011; 123:316-24. [PMID: 20636450 DOI: 10.1111/j.1600-0404.2010.01398.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECTIVES To estimate dementia prevalence in Spain. MATERIALS AND METHODS Nine probabilistic and geographically defined samples participated. A screening design based on the MMSE was implemented. Positively screened individuals underwent clinical evaluation. The total number of cases in Spain was estimated. Prevalence was confronted to that of other European countries. RESULTS Five hundred and forty-six persons aged ≥75 participated, 49 had dementia (35 with Alzheimer's disease [AD], 10 with vascular dementia [VD], 4 other; 25 first diagnosed in the study). Age- and sex-adjusted prevalence and estimated nationwide cases were 7.5% (95% CI 5.4-9.7), 5.6 (95% CI 3.7-7.5) and 1.4 (95% CI 0.5-2.3), and 290,000 (95% CI 208,000-372,000), 214,000 (95% CI 141,000-288,000) and 54,000 (95% CI 20,000-88,000) for dementia, AD and VD, respectively. CONCLUSIONS Dementia prevalence in Spain is comparable to other European populations, while a high number of undiagnosed cases live in the community. The potential impact of Mediterranean diet, hypertension control and decreasing vascular risk factors is discussed.
Collapse
Affiliation(s)
- J Virués-Ortega
- National Centre for Epidemiology, Research Network in Nerodegenerative Disease, Carlos III Institute of Health, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Virués-Ortega J, de Pedro-Cuesta J, Seijo-Martínez M, Saz P, Sánchez-Sánchez F, Rojo-Pérez F, Rodríguez F, Mateos R, Martínez-Martín P, Mahillo I, Gascon-Bayarri J, Garre-Olmo J, García FJ, Fernández-Mayoralas G, Bermejo-Pareja F, Bergareche A, Almazan-Isla J, del Barrio JL. Prevalence of disability in a composite ≥75 year-old population in Spain: a screening survey based on the International Classification of Functioning. BMC Public Health 2011; 11:176. [PMID: 21429194 PMCID: PMC3070655 DOI: 10.1186/1471-2458-11-176] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2010] [Accepted: 03/23/2011] [Indexed: 11/20/2022] Open
Abstract
Background The prevalence and predictors of functional status and disability of elderly people have been studied in several European countries including Spain. However, there has been no population-based study incorporating the International Classification of Functioning, Disability and Health (ICF) framework as the basis for assessing disability. The present study reports prevalence rates for mild, moderate, and severe/extreme disability by the domains of activities and participation of the ICF. Methods Nine populations surveyed in previous prevalence studies contributed probabilistic and geographically defined samples in June 2005. The study sample was composed of 503 subjects aged ≥75 years. We implemented a two-phase screening design using the MMSE and the World Health Organization-Disability Assessment Schedule 2nd edition (WHO-DAS II, 12 items) as cognitive and disability screening tools, respectively. Participants scoring within the positive range of the disability screening were administered the full WHO-DAS II (36 items; score range: 0-100) assessing the following areas: Understanding and communication, Getting along with people, Life activities, Getting around, Participation in society, and Self-care. Each disability area assessed by WHO-DAS II (36 items) was reported according to the ICF severity ranges (No problem, 0-4; Mild disability, 5-24; Moderate disability, 25-49; Severe/Extreme disability, 50-100). Results The age-adjusted disability prevalence figures were: 39.17 ± 2.18%, 15.31 ± 1.61%, and 10.14 ± 1.35% for mild, moderate, and severe/extreme disability, respectively. Severe and extreme disability prevalence in mobility and life activities was three times higher than the average, and highest among women. Sex variations were minimal, although life activities for women of 85 years and over had more severe/extreme disability as compared to men (OR = 5.15 95% CI 3.19-8.32). Conclusions Disability is highly prevalent among the Spanish elderly. Sex- and age-specific variations of disability are associated with particular disability domains.
Collapse
Affiliation(s)
- Javier Virués-Ortega
- Research Network in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Cubo E, Martinez Martin P, Gonzalez M, Bergareche A, Campos V, Fernández JM, Alvárez M, Bayes A. What contributes to driving ability in Parkinson's disease. Disabil Rehabil 2010; 32:374-8. [PMID: 19958153 DOI: 10.3109/09638280903168507] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE To determine the most significant clinical predictors that influence driving ability in Parkinson disease (PD). METHODS National-multi-centre, cross-sectional study covering PD outpatients. Clinical assessment was based on the following questionnaires: cognition (SCOPA-Cog); motor impairment and disabilities (SCOPA motor); depression/anxiety; sleep (SCOPA-Sleep); psychosis and severity/global impairment (HY and CISI-PD). Driving status data was obtained using a standardized questionnaire. Comparisons between drivers and ex-drivers were calculated using chi(2) and Student t-tests as appropriate. Multi-variate logistic regression analysis was performed to identify independent driving ability clinical predictors. RESULTS Compared with the drivers, the ex-drivers were older (p = 0.00005), had longer disease duration (p = 0.03), had more overall cognitive dysfunction (p = 0.004) and had greater motor impairment, as measured by the CISI (p = 0.02), HY stage (p = 0.034) and by the SCOPA-motor scale (p = 0.002) and difficulty in activities of daily life (p = 0.002). In the regression model analysis, aging and ADL impairment were the principal clinical predictors that differentiated drivers from ex-drivers. CONCLUSIONS Although overall driving impairment in PD is associated with advancing disease severity, driving ability seems to be more strongly influenced by age and ADL impairment. Multi-disciplinary teams are required to assess driving ability in patients with PD and develop rehabilitation measures for safer driving.
Collapse
Affiliation(s)
- Esther Cubo
- Neurology Department, Hospital General Yague, Burgos, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Ruiz-Martínez J, Gorostidi A, Ibañez B, Alzualde A, Otaegui D, Moreno F, de Munain AL, Bergareche A, Gómez-Esteban JC, Massó JFM. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Mov Disord 2010; 25:2340-5. [DOI: 10.1002/mds.23278] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
31
|
Moreno F, Indakoetxea B, Barandiaran M, Alzualde A, Gabilondo A, Estanga A, Ruiz J, Ruibal M, Bergareche A, Martí-Massó JF, López de Munain A. "Frontotemporoparietal" dementia: clinical phenotype associated with the c.709-1G>A PGRN mutation. Neurology 2009; 73:1367-74. [PMID: 19858458 DOI: 10.1212/wnl.0b013e3181bd82a7] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Mutations in the progranulin gene (PGRN) are a major cause of frontotemporal lobar degeneration with tau-negative and ubiquitin-positive neuronal inclusions. Most previous studies aimed at characterizing the clinical and neuropsychological phenotype of PGRN mutation carriers included patients with different PGRN mutations, assuming that the common proposed pathogenetic mechanism of haploinsufficiency will lead to a comparable phenotype. METHODS We studied 21 patients with a single pathogenic splicing mutation in the PGRN gene (c.709-1G>A) in the same tertiary referral center using homogenous diagnostic criteria and protocols. All patients were of Basque descent. RESULTS Patients exhibited a variable phenotype both in age at onset and initial symptoms. Behavioral variant frontotemporal dementia (52.4%) and progressive nonfluent aphasia (23.8%) were the most common presenting syndromes. Apathy was the most common behavioral symptom. Patients developed a relatively rapidly progressive dementia with features that led to a secondary diagnosis in 61.9% of cases 2 years after primary diagnosis. Notably, this secondary or tertiary diagnosis was corticobasal syndrome in 47.6% of cases, which confirmed the neuropsychological features of parietal lobe dysfunction seen at the initial assessment in 81.8% of patients. CONCLUSIONS Patients carrying the c.709-1G>A mutation in the PGRN gene showed heterogeneous clinical and neuropsychological features and commonly developed corticobasal syndrome as the disease progressed.
Collapse
Affiliation(s)
- F Moreno
- Department of Neurology, Hospital Donostia, Paseo Dr. Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
de Pedro-Cuesta J, Virués-Ortega J, Vega S, Seijo-Martínez M, Saz P, Rodríguez F, Rodríguez-Laso A, Reñé R, de las Heras SP, Mateos R, Martínez-Martín P, Manubens JM, Mahillo-Fernandez I, López-Pousa S, Lobo A, Reglà JL, Gascón J, García FJ, Fernández-Martínez M, Boix R, Bermejo-Pareja F, Bergareche A, Benito-León J, de Arce A, del Barrio JL. Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990-2008. BMC Neurol 2009; 9:55. [PMID: 19840375 PMCID: PMC2770986 DOI: 10.1186/1471-2377-9-55] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Accepted: 10/19/2009] [Indexed: 12/04/2022] Open
Abstract
Background This study describes the prevalence of dementia and major dementia subtypes in Spanish elderly. Methods We identified screening surveys, both published and unpublished, in Spanish populations, which fulfilled specific quality criteria and targeted prevalence of dementia in populations aged 70 years and above. Surveys covering 13 geographically different populations were selected (prevalence period: 1990-2008). Authors of original surveys provided methodological details of their studies through a systematic questionnaire and also raw age-specific data. Prevalence data were compared using direct adjustment and logistic regression. Results The reanalyzed study population (aged 70 year and above) was composed of Central and North-Eastern Spanish sub-populations obtained from 9 surveys and totaled 12,232 persons and 1,194 cases of dementia (707 of Alzheimer's disease, 238 of vascular dementia). Results showed high variation in age- and sex-specific prevalence across studies. The reanalyzed prevalence of dementia was significantly higher in women; increased with age, particularly for Alzheimer's disease; and displayed a significant geographical variation among men. Prevalence was lowest in surveys reporting participation below 85%, studies referred to urban-mixed populations and populations diagnosed by psychiatrists. Conclusion Prevalence of dementia and Alzheimer's disease in Central and North-Eastern Spain is higher in females, increases with age, and displays considerable geographic variation that may be method-related. People suffering from dementia and Alzheimer's disease in Spain may approach 600,000 and 400,000 respectively. However, existing studies may not be completely appropriate to infer prevalence of dementia and its subtypes in Spain until surveys in Southern Spain are conducted.
Collapse
Affiliation(s)
- Jesús de Pedro-Cuesta
- National Centre for Epidemiology, CIBERNED and Alzheimer' Disease Research Unit, Carlos III Institute of Public Health, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ruiz-Martínez J, Arratibel-Echarren I, Gorostidi-Pagola A, Bergareche A, Martí-Massó JF. [Tremor: update and controversy]. Rev Neurol 2009; 48 Suppl 1:S37-S41. [PMID: 19222014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
INTRODUCTION Tremor is the most common movement disorder. The differential diagnosis on its origin is sometimes difficult and the number of conditions that include this symptom as part of their clinical spectrum continues to increase. AIMS To provide an update on aspects that may help in the process of diagnosis, to review the main lines of therapy and to reflect on tremor within the context of Parkinson's disease. DEVELOPMENT Complementary techniques in the study of Parkinson's disease, such as DaT-SCAN or the study of the cardiac sympathetic pathway by means of cardiac scintigraphy with meta-iodobenzylguanidine (MIBG), have helped in the aetiological diagnosis of this symptom; nevertheless, the patient's clinical history continues to be the main source of information for an accurate diagnosis. Pharmacologically, the therapeutic approach has varied very little and the outcomes of surgical procedures are still described as an alternative in medication-resistant cases. In Parkinson's disease, tremor at rest is a characteristic clinical sign that comprises a series of peculiarities, and the interrelation between essential tremor and this disease is always a controversial issue. The appearance of cases that have been diagnosed as Parkinson's disease, but in which the nigrostriatal pathway remains intact, opens up the spectrum even wider. CONCLUSIONS In this paper we review the data available today that help in the differential diagnosis of tremor; the particularities concerning Parkinson's disease from the diagnostic, therapeutic and genotypic point of view are also discussed.
Collapse
Affiliation(s)
- J Ruiz-Martínez
- Servicio de Neurología, Hospital Donostia, P. Doctor Beguiristain, s/n. E-20014 San Sebastián, Guipúzcoa, España.
| | | | | | | | | |
Collapse
|
34
|
Ruiz Martínez J, Arratíbel Echarren I, Gorostidi Pagola A, Bergareche A, Martí Massó JF. El temblor: actualidad y controversias. Rev Neurol 2009. [DOI: 10.33588/rn.48s01.2008692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
35
|
López de Munain A, Alzualde A, Gorostidi A, Otaegui D, Ruiz-Martínez J, Indakoetxea B, Ferrer I, Pérez-Tur J, Sáenz A, Bergareche A, Barandiarán M, Poza JJ, Zabalza R, Ruiz I, Urtasun M, Fernández-Manchola I, Olasagasti B, Espinal JB, Olaskoaga J, Ruibal M, Moreno F, Carrera N, Martí Massó JF. Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings. Biol Psychiatry 2008; 63:946-52. [PMID: 17950702 DOI: 10.1016/j.biopsych.2007.08.015] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2007] [Revised: 07/26/2007] [Accepted: 08/29/2007] [Indexed: 01/28/2023]
Abstract
BACKGROUND There is an increasing interest in the clinico-pathological correlation of mutations in progranulin (PGRN) and frontotemporal lobar degeneration (FTLD) complex diseases. We aim to study the PGRN expression variability in patients with different clinical features for a better understanding of its roles in FTLD disease. METHODS We sequenced the PGRN gene in 72 patients suffering from FTLD (25 familial and 47 sporadic cases) and in 24 asymptomatic at-risk relatives. We also analyzed PGRN expression in blood by quantitative real-time polymerase chain reaction from 37 patients, 8 asymptomatic mutation carriers, and 10 control subjects as well as in brain tissue from 16 patients and 9 control subjects. RESULTS Four novel mutations were associated with familial and sporadic FTLD and familial dementia associated with amyotrophic lateral sclerosis. We identified a close association between the IVS6-1G>A mutation in PGRN and corticobasal syndrome. Brain tissue was available for carriers of two of the four mutations (IVS6-1 G>A and P357HfsX3). Immunohistochemical analysis revealed ubiquitin- and TDP-43positive and tau/alpha-synuclein negative immunoreactive neuronal intranuclear inclusions. The relative expression of PGRN in the clinical sample was significantly lower in carriers of the IVS6-1 G>A than in control subjects. CONCLUSIONS Progranulopathies are a major cause of the main phenotypes included in the FTLD complex. According to our results, the level of expression of PGRN in blood could be a useful marker both for diagnostics of part of the spectrum of FTLD conditions and for monitoring future treatments that might boost the level of PGRN in this disorder.
Collapse
|
36
|
Martínez Martín P, Frades Payo B, Rodríguez Blázquez C, Forjaz MJ, de Pedro Cuesta J, Grupo ELEP AA, Chacón Peña JR, García Ruiz-Espiga PJ, López del Val LJ, Carballo Cordero M, Linazasoro Cristóbal G, Aguilar Barberà M, Kulisevsky Bojarsky J, Vivancos Matellano F, Vela Desojo L, Valldeoriola Serra F, Bayés Rusiñol MA, Blázquez Estrada M, Catalán Alonso MJ, Cubo Delgado E, Fernández García JM, Martínez Castrillo JC, Mendoza Rodríguez A, Posada Rodríguez IJ, Campos Arillo VM, Mir Rivera P, Álvarez Saúco M, Díaz Negrillo A, Bergareche A, Quílez Ferrer P. Atributos psicométricos de la Scales for Outcomes in Parkinson’s Disease-Cognition (SCOPA-Cog), versión en castellano. Rev Neurol 2008. [DOI: 10.33588/rn.4707.2008430] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
del Barrio JL, Medrano MJ, Arce A, Bergareche A, Bermejo F, Díaz J, Gascón J, García FJ, Garré J, Gómez C, Lobo A, Martínez A, Otero A, Reñé R, Sánchez MI, Saz P, Vega S, Vilalta-Franch J, Zunzunegui MV, de Pedro J. [Prevalence of vascular risk factors among Spanish populations aged 70 years and over, as reported in door-to-door studies on neurological diseases]. Neurologia 2007; 22:138-46. [PMID: 17364251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023] Open
Abstract
INTRODUCTION The aim of this study was to re-analyze door-to-door studies on neurological diseases among the elderly, in which vascular risk factors (VRF) were studied, describing methodological characteristics and prevalence of VRF. METHODS The surveys were identified in two phases. They were aimed at ascertaining prevalence of stroke, dementias or Parkinsonisms and, at the time of individual screening, had collected data on at least three of the following VRF: arterial hypertension (AHT), smoking habit, diabetes mellitus and hypercholesterolemia. A questionnaire was drawn up to collect the data reported in each study, and a database was constructed. VRF prevalences were quantified and analyzed using logistic regression. RESULTS The total of the re-analyzed population was 12,510 persons aged 70 years and over, residents in seven geographic areas during the period 1994-2002. Information available on VRF was essentially self-reported. The prevalence of self-reported AHT was 25.7 % in men and 44.2 % in women, and that of measured AHT was 61 % and 71.9 %, respectively. Populations with arterial pressure obtained by direct measurement registered 138 higher risks (OR: 1.74; 95 % CI: 1.51-2.01, and OR: 1.48; 95% CI: 1.33-1.64). Reported prevalence of diabetes, hypercholesterolemia and smoking habit were 14.3 %, 23.3% and 8.5 %, respectively. CONCLUSIONS There was a high prevalence of VRF among the Spanish elderly population. However, its relationship with dementia, Parkinsonisms and cerebrovascular disease could not be studied due to the poor quality of the VRF data. The differences between measured and self-reported arterial pressure suggest the existence of undetected AHT and wide scope for prevention.
Collapse
Affiliation(s)
- J L del Barrio
- Instituto de Salud Carlos III, Centro Nacional de Epidemiología, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Martínez-Martín P, Cubo-Delgado E, Aguilar-Barberà M, Bergareche A, Escalante S, Rojo A, Campdelacreu J, Frades-Payo B, Arroyo S. [A pilot study on a specific measure for sleep disorders in Parkinson's disease: SCOPA-Sleep]. Rev Neurol 2006; 43:577-83. [PMID: 17099848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
INTRODUCTION There is a high prevalence of sleep disorders in Parkinson's disease (PD). AIMS. To assess some basic metric attributes of the SCOPA-Sleep scale, a measure for PD patients; secondary objective: to check the impact caused by the sleep disorder on the health-related quality of life (HRQoL) of patients and their caregivers. SUBJECTS AND METHODS 68 PD patients and their main caregivers; measures: Hoehn and Yahr staging, SCOPA-Motor, Clinical Impression of Severity Index (CISI-PD), PDSS, Hospital Anxiety and Depression Scale, SCOPA-Psychosocial, and EuroQoL. Carers filled in a PDSS questionnaire about patient sleep and HRQoL measures (SF-36, EuroQoL). SCOPA-Sleep acceptability, scaling assumptions, internal consistency, construct validity and precision were determined. RESULTS SCOPA-Sleep acceptability and scaling assumptions resulted satisfactory, although the nocturnal sleep subescale (SC-Ns) showed a mild ceiling effect (22.1%) and a defective convergent validity was found for daytime sleepiness (SC-Ds) item 6. Internal consistency also was satisfactory for both scales (alpha = 0.84 and 0.75, respectively). The correlation between SC-Ns and PDSS was high (rs = -0.70), as it was between SC-Ns and PDSS questionnaire by caregiver (rs = -0.53). The corresponding coefficients with the SC-Ds gained lower values (rs = -0.41 y -0.50). Standard error of measurement was 1.45 for the SC-Ns and 1.76 for the SC-Ds. Both, patient and caregiver HRQoL showed a loose association with the sleep measures. CONCLUSION SCOPA-Sleep is a feasible, consistent, and useful scale for assessment of sleep disorder in PD patients. A weak association between sleep disorder and HRQoL was found.
Collapse
Affiliation(s)
- P Martínez-Martín
- Sección de Neuroepidemiología, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, 28029 Madrid, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Boix R, del Barrio JL, Saz P, Reñé R, Manubens JM, Lobo A, Gascón J, de Arce A, Díaz-Guzmán J, Bergareche A, Bermejo-Pareja F, de Pedro-Cuesta J. Stroke prevalence among the Spanish elderly: an analysis based on screening surveys. BMC Neurol 2006; 6:36. [PMID: 17042941 PMCID: PMC1626484 DOI: 10.1186/1471-2377-6-36] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2006] [Accepted: 10/16/2006] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND This study sought to describe stroke prevalence in Spanish elderly populations and compare it against that of other European countries. METHODS We identified screening surveys--both published and unpublished--in Spanish populations, which fulfilled specific quality requirements and targeted prevalence of stroke in populations aged 70 years and over. Surveys covering seven geographically different populations with prevalence years in the period 1991-2002 were selected, and the respective authors were then asked to provide descriptions of the methodology and raw age-specific data by completing a questionnaire. In addition, five reported screening surveys in European populations furnished useful data for comparison purposes. Prevalence data were combined, using direct adjustment and logistic regression. RESULTS The overall study population, resident in central and north-eastern Spain, totalled 10,647 persons and yielded 715 cases. Age-adjusted prevalences, using the European standard population, were 7.3% for men, 5.6% for women, and 6.4% for both sexes. Prevalence was significantly lower in women, OR 0.79 95% CI 0.68-0.93, increased with age, particularly among women, and displayed a threefold spatial variation with statistically significant differences. Prevalences were highest, 8.7%, in suburban, and lowest, 3.8%, in rural populations. Compared to pooled Spanish populations, statistically significant differences were seen in eight Italian populations, OR 1.39 95% CI (1.18-1.64), and in Kungsholmen, Sweden, OR 0.40 95% CI (0.27-0.58). CONCLUSION Prevalence in central and north-eastern Spain is higher in males and in suburban areas, and displays a threefold geographic variation, with women constituting the majority of elderly stroke sufferers. Compared to reported European data, stroke prevalence in Spain can be said to be medium and presents similar age- and sex-specific traits.
Collapse
Affiliation(s)
- Raquel Boix
- National Centre for Epidemiology, Carlos III Institute of Public Health, Madrid, Spain
| | - José Luis del Barrio
- National Centre for Epidemiology, Carlos III Institute of Public Health, Madrid, Spain
| | - Pedro Saz
- Department of Medicine and Psychiatry, Zaragoza University, Zaragoza, Spain
| | - Ramón Reñé
- Dementia Diagnosis and Treatment Unit, Neurology Department, Bellvitge University Teaching Hospital, Barcelona, Spain
| | | | - Antonio Lobo
- Department of Medicine and Psychiatry, Zaragoza University, Zaragoza, Spain
| | - Jordi Gascón
- Dementia Diagnosis and Treatment Unit, Neurology Department, Bellvitge University Teaching Hospital, Barcelona, Spain
| | - Ana de Arce
- Neurology Department, Donostia Hospital, Guipúzcoa, Spain
| | - Jaime Díaz-Guzmán
- Neurology Department, 12 de Octubre University Teaching Hospital, Madrid, Spain
| | | | | | - Jesús de Pedro-Cuesta
- National Centre for Epidemiology, Carlos III Institute of Public Health, Madrid, Spain
| |
Collapse
|
40
|
Martínez Martín P, Cubo Delgado E, Aguilar Barberà M, Bergareche A, Escalante Arroyo S, Rojo Sebastián A, Campdelacreu J, Frades Payo B, Arroyo Velasco S, Menéndez Guisasola L, Grupo ELEP AA, Salvador Aguiar C, González González S, Bayés Rusiñol MA, Valldeoriola Serra F, Vela Desojo L, Benito León J, Vivancos Matellano F, Catalán Alonso MJ, García Muñozguren S, Durán Herrera C, Duarte García-Luis J, Martínez Castrillo JC, Mendoza Rodríguez A, Rodríguez Sanz MF, López del Val LJ, Chacón Peña JR, Carballo Cordero M, Fernández García JM, Campos Arillo VM, Álvarez Saúco M, Leiva Santana C, Castro García A, Sesar Ignacio Á, Ortega Moreno Á, Luquin Piudo MR. Estudio piloto sobre una medida específica para los trastornos del sueño de la enfermedad de Parkinson: SCOPA-Sueño. Rev Neurol 2006. [DOI: 10.33588/rn.4310.2006307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Grupo ELEP AA, Martínez Martín P, Linazasoro Cristóbal G, Kulisevsky Bojarsky J, Aguilar Barberà M, de Pedro Cuesta J, Cubo Delgado E, Forjaz MJ, Bergareche A, Martínez Castrillo JC, Blázquez Estrada M, Menéndez Guisasola L, Salvador Aguiar C, González González S, Bayés Rusiñol MA, Vela Desojo L, Balseiro Gómez JJ, Ortega Moreno Á, García Muñozguren S, Frades Payo B, Arroyo Velasco S, Durán Herrera C, Duarte García-Luis J, Mendoza Rodríguez A, Rodríguez Sanz MF, López del Val LJ, Chacón Peña JR, Fernández García JM, Benito León J, Campos Arillo VM, Vivancos Matellano F, Rojo Sebastián A, Álvarez Saúco M, Leiva Santana C, Mir Rivera P, Carballo Cordero M, Palomino García A, Burguera Hernández JA, Catalán Alonso MJ, Luquin Piudo MR. Estudio longitudinal de pacientes con enfermedad de Parkinson (ELEP): objetivos y metodología. Rev Neurol 2006. [DOI: 10.33588/rn.4206.2006041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Bergareche A, Martí-Massó JF, Linacasoro G, Arrinda JM, De Arce A. Early onset parkinsonism in dementia lacking distinct histopathological features. Clin Neuropathol 2006; 25:14-7. [PMID: 16465769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023] Open
Abstract
Dementia lacking distinct histopathological features (DLDHF) belongs to the frontotemporal dementia syndromes. Behavioral, cognitive and motor symptoms are its usual clinical manifestations. However, considerable heterogeneity exists and no evident clinicopathological correlations can be performed. We report a patient who presented with a very unusual combination of behavioral abnormalities and prominent early parkinsonism progressing to a severe dementia. Pathological studies confirmed DLDHF with severe frontal and striatal neuronal loss and gliosis.
Collapse
Affiliation(s)
- A Bergareche
- Department of Neurology, Bidasoa Hospital, Hondarribia, Spain.
| | | | | | | | | |
Collapse
|
43
|
del Barrio JL, de Pedro-Cuesta J, Boix R, Acosta J, Bergareche A, Bermejo-Pareja F, Gabriel R, García de Yébenes MJ, García FJ, López-Pousa S, Manubens JM, Mateos R, Matías-Guiu J, Olivé JM, Reñé R, Rodríguez F, Saz P. Dementia, Stroke and Parkinson’s Disease in Spanish Populations: A Review of Door-to-Door Prevalence Surveys. Neuroepidemiology 2005; 24:179-88. [PMID: 15832058 DOI: 10.1159/000085138] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We identified 14 door-to-door prevalence surveys on dementia, parkinsonism or stroke in Spanish populations fulfilling specific criteria and combined selected age- and sex-specific data using logistic regression and taking Pamplona as a reference. The prevalence of dementia and of Alzheimer's disease varied significantly with space. However, the largest variation was seen for vascular dementia: odds ratio (OR) and 95% confidence interval (CI) for Gerona were 6.42 (3.23-12.3) in women and 2.30 (1.10-4.79) in men. Stroke was particularly frequent among Arevalo's women, with OR 2.10 and 95% CI 1.26-3.49. The prevalence of Parkinson's disease was twofold higher in Cantalejo. Although differences in methodology make the interpretation of results problematic, the prevalence of stroke and vascular dementia in Spain seems to vary spatially, indicating a space for prevention.
Collapse
Affiliation(s)
- José Luis del Barrio
- Centro Nacional de Epidemiología, Instituto de Salud Carlos III, ES-28029 Madrid, España.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Bergareche A, De La Puente E, López de Munain A, Sarasqueta C, de Arce A, Poza JJ, Martí-Massó JF. Prevalence of Parkinson?s disease and other types of Parkinsonism. J Neurol 2004; 251:340-5. [PMID: 15015016 DOI: 10.1007/s00415-004-0333-3] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2003] [Revised: 10/22/2003] [Accepted: 11/06/2003] [Indexed: 10/26/2022]
Abstract
OBJECTIVES To assess the prevalence of Parkinson's disease and parkinsonism in two Spanish populations (Irun and Hondarribia, Bidasoa Region) and to compare the results with those of similar surveys. METHODS The survey included 2000 participants aged 65 years or older in a door-to-door, three-phase design. In the screening phase we used the SNES (Sicilian Neuro-Epidemiologic Study) screening questionnaire, which has 100% sensitivity. In phases 2 and 3 we carried out a 3-year follow-up of all cases diagnosed with parkinsonism in phase 2. Progressively stricter diagnostic criteria were chosen in order to minimize the impact of false positives on the final results. RESULTS The prevalence of Parkinson's disease (PD) was 1.5 % (95% confidence interval, 0.9 to 2.3) and the prevalence of other types of parkinsonism (OP) was 1.1 % (95% confidence interval 0.6 to 1.9). The overall prevalence by age group was 0.4 % (65-74 years), 4.7% (75-84 years), and 2.9% (> or =85 years) for Parkinson's disease and 0.7%, 2%, and 3.9 % for parkinsonism, respectively. The other parkinsonism prevalence was 1.3 % in men and 1.6 % in women. CONCLUSIONS These prevalence rates are similar than those found in studies made in other European countries. The prevalence of both Parkinson's disease and other types of parkinsonism increased with age, with no significant differences between men and women.
Collapse
Affiliation(s)
- A Bergareche
- Dept of Neurology, Bidasoa Hospital, Bidasoa, Spain.
| | | | | | | | | | | | | |
Collapse
|
45
|
Sarasqueta C, Bergareche A, Arce A, Lopez de Munain A, Poza JJ, De La Puente E, Urtasun M, Emparanza JE, Martí Masso JF. The validity of Hodkinson's Abbreviated Mental Test for dementia screening in Guipuzcoa, Spain. Eur J Neurol 2001; 8:435-40. [PMID: 11554906 DOI: 10.1046/j.1468-1331.2001.00246.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The objective of this research was to evaluate the validity of Hodkinson's Abbreviated Mental Test (AMT) in screening for dementia and to identify the optimum cut-off point to use in a prevalence survey. The study included two groups of persons: (i) a random sample of 183 individuals selected from census data, 96 of whom completed the study and (ii) another 36 persons with dementia were selected from a hospital outpatients department by sampling consecutive cases. The DSM-IV criteria were used as the "gold standard" to establish a diagnosis of dementia. The AMT was administered to the 132 participants who subsequently underwent independent clinical evaluation. In the community sample, 11 persons were diagnosed with dementia and 85 without. In the total sample, a score of 7 maximizes the efficacy of the test. The sensitivity for this cut-off point is 91.5% (78.7-97.2%) and the specificity is 82.4% (72.2-89.5%). A score of 9 gives 100% sensitivity, but the proportion of false positives rises to 66%. Our results are consistent with other studies and suggest that the AMT is a valid instrument for use in screening for dementia in populations similar to the one in this study.
Collapse
Affiliation(s)
- C Sarasqueta
- Unidad de Epidemiología Clínica, Hospital Aránzazu, P. Dr Beguiristain s/n, 20.014 Donostia-San Sebastian, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bergareche A, De La Puente E, López De Munain A, Sarasqueta C, De Arce A, Poza JJ, Martí-Massó JF. Prevalence of Essential Tremor: A Door-to-Door Survey in Bidasoa, Spain. Neuroepidemiology 2001; 20:125-8. [PMID: 11359080 DOI: 10.1159/000054771] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVES To assess the prevalence of essential tremor (ET) in two Spanish populations (Irun and Hondarribia, Bidasoa region) and to compare the results with those of similar surveys. METHODS The survey included 2,000 participants aged 65 years or older in a door-to-door, two-phase design. ET was defined as postural or kinetic tremor of the head or limbs. RESULTS ET prevalence after age adjustment was 4.8% (95% confidence interval, 3.6-6.4). Prevalence increased significantly with age and there were no sex differences. CONCLUSIONS The age-adjusted prevalence rate of ET in people 65 years old and older in Bidasoa, Spain, is close to those described in other studies using a similar design and suggest no geographical variation. ET prevalence increases with age and has a similar distribution in males and females.
Collapse
Affiliation(s)
- A Bergareche
- Department of Neurology, Hospital Bidasoa, Hondarribia, Spain.
| | | | | | | | | | | | | |
Collapse
|